Longboard Non Current Assets Total from 2010 to 2024
| LBPH Stock | USD 59.91 0.11 0.18% |
Non Current Assets Total | First Reported 2010-12-31 | Previous Quarter 476 K | Current Value 539.6 K | Quarterly Volatility 144.1 K |
Check Longboard Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Longboard Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 2.3 M, Interest Income of 2.3 M or Depreciation And Amortization of 3.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.92. Longboard financial statements analysis is a perfect complement when working with Longboard Pharmaceuticals Valuation or Volatility modules.
Longboard | Non Current Assets Total |
Latest Longboard Pharmaceuticals' Non Current Assets Total Growth Pattern
Below is the plot of the Non Current Assets Total of Longboard Pharmaceuticals over the last few years. It is the total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets. Longboard Pharmaceuticals' Non Current Assets Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Longboard Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Current Assets Total | 10 Years Trend |
|
Non Current Assets Total |
| Timeline |
Longboard Non Current Assets Total Regression Statistics
| Arithmetic Mean | 799,840 | |
| Geometric Mean | 784,941 | |
| Coefficient Of Variation | 18.01 | |
| Mean Deviation | 111,701 | |
| Median | 876,000 | |
| Standard Deviation | 144,080 | |
| Sample Variance | 20.8B | |
| Range | 400K | |
| R-Value | (0.72) | |
| Mean Square Error | 10.8B | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | (23,131) | |
| Total Sum of Squares | 290.6B |
Longboard Non Current Assets Total History
About Longboard Pharmaceuticals Financial Statements
Investors use fundamental indicators, such as Longboard Pharmaceuticals' Non Current Assets Total, to determine how well the company is positioned to perform in the future. Although Longboard Pharmaceuticals' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Non Current Assets Total | 476 K | 539.6 K |
Currently Active Assets on Macroaxis
When determining whether Longboard Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Longboard Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Longboard Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Longboard Pharmaceuticals Stock:Check out the analysis of Longboard Pharmaceuticals Correlation against competitors. For more detail on how to invest in Longboard Stock please use our How to Invest in Longboard Pharmaceuticals guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Longboard Pharmaceuticals. If investors know Longboard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Longboard Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.25) | Return On Assets (0.31) | Return On Equity (0.47) |
The market value of Longboard Pharmaceuticals is measured differently than its book value, which is the value of Longboard that is recorded on the company's balance sheet. Investors also form their own opinion of Longboard Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Longboard Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Longboard Pharmaceuticals' market value can be influenced by many factors that don't directly affect Longboard Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Longboard Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Longboard Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Longboard Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.